IBRX

Immunitybio Inc

IBRX, USA

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.

https://immunitybio.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
IBRX
stock
IBRX

ImmunityBio Appoints Bruce Wendel to Board TipRanks

Read more →
IBRX
stock
IBRX

ImmunityBio (NASDAQ:IBRX) Stock Price Down 7.8% - Here's Why MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$10.2

Analyst Picks

Strong Buy

3

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-3.92

Low 1

High 3

Return on Equity (ROE)

-

Low

11.80 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-12.96 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-217.24 %

Low 5%

High 15%

Investors

* Institutions hold a combined 15.18% of the total shares of Immunitybio Inc

1.

Vanguard Group Inc

(2.3081%)

since

2025/06/30

2.

BlackRock Inc

(1.8796%)

since

2025/06/30

3.

Bank of America Corp

(0.9263%)

since

2025/06/30

4.

Armistice Capital, LLC

(0.8214%)

since

2025/06/30

5.

Jane Street Group LLC

(0.8165%)

since

2025/06/30

6.

State Street Corp

(0.8057%)

since

2025/06/30

7.

Vanguard Total Stock Mkt Idx Inv

(0.7711%)

since

2025/07/31

8.

Geode Capital Management, LLC

(0.6112%)

since

2025/06/30

9.

iShares Russell 2000 ETF

(0.5796%)

since

2025/08/31

10.

Vanguard Small Cap Index

(0.5672%)

since

2025/07/31

11.

Woodline Partners LP

(0.3645%)

since

2025/06/30

12.

Millennium Management LLC

(0.3432%)

since

2025/06/30

13.

SPDR® S&P Biotech ETF

(0.3254%)

since

2025/08/31

14.

Vanguard Small Cap Growth Index Inv

(0.3169%)

since

2025/07/31

15.

AlphaCore Capital LLC

(0.3147%)

since

2025/06/30

16.

Morgan Stanley - Brokerage Accounts

(0.3144%)

since

2025/06/30

17.

Citigroup Inc

(0.2631%)

since

2025/06/30

18.

TANG CAPITAL MANAGEMENT LLC

(0.2468%)

since

2025/06/30

19.

Fidelity Small Cap Index

(0.244%)

since

2025/06/30

20.

Vanguard Institutional Extnd Mkt Idx Tr

(0.2314%)

since

2025/07/31

21.

Susquehanna International Group, LLP

(0.1959%)

since

2025/06/30

22.

Northern Trust Corp

(0.1951%)

since

2025/06/30

23.

Charles Schwab Investment Management Inc

(0.1878%)

since

2025/06/30

24.

iShares Russell 2000 Growth ETF

(0.1747%)

since

2025/08/31

25.

Royal Bank of Canada

(0.1296%)

since

2025/06/30

26.

UBS Group AG

(0.126%)

since

2025/06/30

27.

Fidelity Extended Market Index

(0.1165%)

since

2025/07/31

28.

Vanguard Russell 2000 ETF

(0.116%)

since

2025/07/31

29.

JPMorgan Chase & Co

(0.1134%)

since

2025/06/30

30.

Schwab US Small-Cap ETF™

(0.1009%)

since

2025/08/30

31.

BSC Private Wealth Management, LLC

(0.0895%)

since

2025/06/30

32.

State St Russell Sm Cap® Indx SL Cl I

(0.0859%)

since

2025/08/31

33.

JPM Thematics Genetic Thrps C2 dist USD

(0.0846%)

since

2025/07/31

34.

Vanguard Health Care ETF

(0.0721%)

since

2025/07/31

35.

Schwab Small Cap Index

(0.0625%)

since

2025/07/31

36.

NT R2000 Index Fund - NL

(0.0589%)

since

2025/06/30

37.

iShares Biotechnology ETF

(0.0574%)

since

2025/08/31

38.

Fidelity Nasdaq Composite Index

(0.0565%)

since

2025/07/31

39.

iShares Nasdaq US Biotech ETF USD Acc

(0.0548%)

since

2025/08/31

40.

NT R2000 Index Fund - DC - NL - 3

(0.047%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.1143

Latest Release

Date

2025-09-30

EPS Actual

-0.07

EPS Estimate

-0.1071

EPS Difference

0.0371

Surprise Percent

34.6405%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(2.5)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(1.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.